Replies to post #82846 on Triple 000 and Sub-penny Chart Plays

[TPX]

$MCET OneMedMarket / Stephen Chang, Ph.D., Scientific Advisor (Co-Chair)

As the Vice President for Research and Development at The New York Stem Cell Foundation, Dr. Stephen Chang has overall responsibility for planning, coordinating, and managing the activities of the research department. In this role, he provides senior leadership in the areas of research and development, oversight of short and long term projects with regulations and policies related to administration and business units, partnerships with industry and other research institutions, and monitoring and evaluation of projects. Prior to joining NYSCF, Dr. Chang served as Chief Scientific Officer of Stemgent upon the company's founding in 2008. He was previously the CEO of Multicell Technologies and continues as a director of this company. Dr. Chang is president of CURES, a coalition of patient advocates, biotechnology companies, pharmaceutical companies, and venture capitalists dedicated to ensuring the safety, research, and development of innovative lifesaving medications. He is also a board member of Histogen, Inc., a privately held company in regenerative medicine. Dr. Chang received his PhD in biological chemistry, molecular biology, and biochemistry from the University of California, Irvine. Areas of research interest include translational applications of basic science to pharmaceutical products.

http://www.onemedconferences.com/#!2016-advisory-board/cevm

The 2016 Disruptive Growth & Healthcare Conference will feature presentations from CEOs, CFOs, COOs and CMOs of life science companies focusing on solutions to unmet medical needs and growth companies with disruptive technologies.


Attendees will include over 400 institutional investors, accredited investors, family offices, analysts, registered investment advisors, wealth managers. The panels will cover disruptive innovations and business models, regenerative medicine, immunotherapy, grant writing, and finally a discussion regarding NOLs and rights offerings.


Conference host Source Capital has 8 offices, approximately 100 registered representatives, $750 million in assets, 10,000 retail accounts and is a SEC registered investment advisor.


The conference is open to all Financial Advisors, Wealth Managers, Family Offices, Sell-Side Analysts, Institutional Investors, Accredited Investors, and Clients. Those non-investment professionals wishing to attend will be asked to pay a fee of $1200.

http://www.onemedconferences.com/#!disruptive-growth-feb-10/mainPage

[thugnificent]

FLST T53